Is Ironwood Pharmaceuticals Inc (IRWD) overvalued? · P/E 5.7, rev $219.5M
Ironwood Pharmaceuticals Inc (IRWD) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page asks whether Ironwood Pharmaceuticals Inc (IRWD) looks expensive on cached numbers — not a short thesis.
Latest reported IRWD revenue for 2026-06-30 was $219.5M. Net income was $92.1M. IRWD currently screens at market cap $579.4M and trailing P/E 5.7.
IRWD currently screens at market cap $579.4M and trailing P/E 5.7. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IRWD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IRWD stock page for the full model, not this heading.
Not investment advice.